rxstat › Shortages › Nevirapine
Nevirapine shortage status
Partial shortage
Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Nevirapine products are in shortage in Canada (1 of 6 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
In shortage since
Feb 2, 2026
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.
Reports by product
Active shortageMYLAN-NEVIRAPINE
200MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02387727 · since Feb 2, 2026, no end estimate · Shortage of an active ingredient.
ResolvedMYLAN-NEVIRAPINE
200MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02387727 · ended Mar 18, 2025 · Shortage of an active ingredient.
ResolvedMYLAN-NEVIRAPINE
200MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02387727 · ended Mar 3, 2025 · Delay in shipping of the drug.
ResolvedAURO-NEVIRAPINE
200MG · TABLET · AURO PHARMA INC
DIN 02318601 · ended Oct 28, 2024 · Demand increase for the drug.
ResolvedAURO-NEVIRAPINE
200MG · TABLET · AURO PHARMA INC
DIN 02318601 · ended Feb 26, 2024 · Demand increase for the drug.
ResolvedJAMP NEVIRAPINE
200MG · TABLET
TABLET · JAMP PHARMA CORPORATION
DIN 02405776 · ended Sep 2, 2022 · Disruption of the manufacture of the drug.
ResolvedVIRAMUNE XR
400MG · TABLET (EXTENDED-RELEASE) · BOEHRINGER INGELHEIM (CANADA) LTD LTEE
DIN 02367289 · ended Aug 21, 2019 · Other (Please describe in comments)
DiscontinuedVIRAMUNE XR
400MG · TABLET (EXTENDED-RELEASE) · BOEHRINGER INGELHEIM (CANADA) LTD LTEE
DIN 02367289
DiscontinuedVIRAMUNE
200MG · TABLET · BOEHRINGER INGELHEIM (CANADA) LTD LTEE
DIN 02238748
DiscontinuedAPO-NEVIRAPINE XR
400MG · TABLET (EXTENDED-RELEASE) · APOTEX INC
DIN 02427931
ResolvedMYLAN-NEVIRAPINE
200MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02387727 · ended Aug 27, 2018 · Delay in shipping of the drug.
ResolvedAPO-NEVIRAPINE XR
400MG · TABLET (EXTENDED-RELEASE) · APOTEX INC
DIN 02427931 · ended Aug 29, 2017 · Disruption of the manufacture of the drug.
What's happening
Nevirapine is currently affected by an active shortage report filed with Health Canada by MYLAN PHARMACEUTICALS ULC.
The reported cause is: shortage of an active ingredient. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Nevirapine is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AG).
Recent changes
Common questions
When will Nevirapine be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Nevirapine in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Guides: what to do when your medication is in shortage · how to read shortage reports
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.